Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 512 entries
Sorted by: Best Match Show Resources per page
High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease.

Leukemia & lymphoma

Bezwoda WR, Dansey R.
PMID: 27456411
Leuk Lymphoma. 1989;1(1):71-5. doi: 10.3109/10428198909042462.

Eleven patients with Hodgkin's disease relapsed from or refractory to conventional-dose chemotherapeutic regimens including MOPP and ABVD were treated by means of high-dose chemotherapy (either single agent melphalan or high-dose cyclophosphamide. VP 16 and BCNU) with bone-marrow rescue (autologous...

Cite
Bezwoda WR, Dansey R. High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease. Leuk Lymphoma. 1989;1(1):71-5doi: 10.3109/10428198909042462.
Bezwoda, W. R., & Dansey, R. (1989). High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease. Leukemia & lymphoma, 1(1), 71-5. https://doi.org/10.3109/10428198909042462
Bezwoda, W R, and Dansey, R. "High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease." Leukemia & lymphoma vol. 1,1 (1989): 71-5. doi: https://doi.org/10.3109/10428198909042462
Bezwoda WR, Dansey R. High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease. Leuk Lymphoma. 1989;1(1):71-5. doi: 10.3109/10428198909042462. PMID: 27456411.
Copy Download .nbib Format: NLM
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma.

Experimental hematology & oncology

Koerber RM, Held SAE, Heine A, Kotthoff P, Daecke SN, Bringmann A, Brossart P.
PMID: 26251761
Exp Hematol Oncol. 2015 Aug 05;4:21. doi: 10.1186/s40164-015-0016-z. eCollection 2015.

BACKGROUND: Multiple myeloma (MM) is a clonal B cell malignancy characterized by proliferation of malignant plasma cells in the bone marrow. Despite high-dose melphalan therapy with autologous stem cell transplantation (ASCT) and the introduction of immunomodulatory drugs like bortezomib...

Cite
Koerber RM, Held SAE, Heine A, et al. Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Exp Hematol Oncol. 2015;4:21doi: 10.1186/s40164-015-0016-z.
Koerber, R. M., Held, S. A. E., Heine, A., Kotthoff, P., Daecke, S. N., Bringmann, A., & Brossart, P. (2015). Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Experimental hematology & oncology, 421. https://doi.org/10.1186/s40164-015-0016-z
Koerber, Ruth-Miriam, et al. "Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma." Experimental hematology & oncology vol. 4 (2015): 21. doi: https://doi.org/10.1186/s40164-015-0016-z
Koerber RM, Held SAE, Heine A, Kotthoff P, Daecke SN, Bringmann A, Brossart P. Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma. Exp Hematol Oncol. 2015 Aug 05;4:21. doi: 10.1186/s40164-015-0016-z. eCollection 2015. PMID: 26251761; PMCID: PMC4526421.
Copy Download .nbib Format: NLM
Cytopathological Evaluation of Ocular Surface and Needle Washings Following Intravitreal Melphalan Injections for Retinoblastoma.

Journal of pediatric ophthalmology and strabismus

Francis JH, Mondesire-Crump I, Marr BP, Brodie SE, Abramson DH.
PMID: 26848591
J Pediatr Ophthalmol Strabismus. 2016;53(2):96-98. doi: 10.3928/01913913-20160311-01. Epub 2016 Feb 04.

PURPOSE: There is concern that injections into eyes with retinoblastoma are dangerous and allow tumor escapement. This study attempted to determine this risk by investigating the presence of malignant cells in ocular surface and needle washings of eyes with...

Cite
Francis JH, Mondesire-Crump I, Marr BP, et al. Cytopathological Evaluation of Ocular Surface and Needle Washings Following Intravitreal Melphalan Injections for Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2016;53(2):96-98doi: 10.3928/01913913-20160311-01.
Francis, J. H., Mondesire-Crump, I., Marr, B. P., Brodie, S. E., & Abramson, D. H. (2016). Cytopathological Evaluation of Ocular Surface and Needle Washings Following Intravitreal Melphalan Injections for Retinoblastoma. Journal of pediatric ophthalmology and strabismus, 53(2), 96-98. https://doi.org/10.3928/01913913-20160311-01
Francis, Jasmine H, et al. "Cytopathological Evaluation of Ocular Surface and Needle Washings Following Intravitreal Melphalan Injections for Retinoblastoma." Journal of pediatric ophthalmology and strabismus vol. 53,2 (2016): 96-98. doi: https://doi.org/10.3928/01913913-20160311-01
Francis JH, Mondesire-Crump I, Marr BP, Brodie SE, Abramson DH. Cytopathological Evaluation of Ocular Surface and Needle Washings Following Intravitreal Melphalan Injections for Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2016;53(2):96-98. doi: 10.3928/01913913-20160311-01. Epub 2016 Feb 04. PMID: 26848591; PMCID: PMC5457357.
Copy Download .nbib Format: NLM
Peritoneal amyloidosis: unusual localization of gastrointestinal amyloidosis.

Clinical journal of gastroenterology

Karoui S, Haddad W, Serghini M, Ghorbel IB, Chebbi F, Azzouz H, Haouet S, Houmen H, Safta ZB, Boubaker J, Filali A.
PMID: 26189519
Clin J Gastroenterol. 2011 Aug;4(4):198-201. doi: 10.1007/s12328-011-0222-0. Epub 2011 May 28.

Amyloidosis is a rare disease that results from the extracellular deposition of amorphous fibrillar protein. It is usually observed in a systemic form. Gastrointestinal involvement is frequent but peritoneal localization is unusual. A 43-year-old male was investigated for nephritic...

Cite
Karoui S, Haddad W, Serghini M, et al. Peritoneal amyloidosis: unusual localization of gastrointestinal amyloidosis. Clin J Gastroenterol. 2011;4(4):198-201doi: 10.1007/s12328-011-0222-0.
Karoui, S., Haddad, W., Serghini, M., Ghorbel, I. B., Chebbi, F., Azzouz, H., Haouet, S., Houmen, H., Safta, Z. B., Boubaker, J., & Filali, A. (2011). Peritoneal amyloidosis: unusual localization of gastrointestinal amyloidosis. Clinical journal of gastroenterology, 4(4), 198-201. https://doi.org/10.1007/s12328-011-0222-0
Karoui, Sami, et al. "Peritoneal amyloidosis: unusual localization of gastrointestinal amyloidosis." Clinical journal of gastroenterology vol. 4,4 (2011): 198-201. doi: https://doi.org/10.1007/s12328-011-0222-0
Karoui S, Haddad W, Serghini M, Ghorbel IB, Chebbi F, Azzouz H, Haouet S, Houmen H, Safta ZB, Boubaker J, Filali A. Peritoneal amyloidosis: unusual localization of gastrointestinal amyloidosis. Clin J Gastroenterol. 2011 Aug;4(4):198-201. doi: 10.1007/s12328-011-0222-0. Epub 2011 May 28. PMID: 26189519.
Copy Download .nbib Format: NLM
Refractory Castleman's Disease.

Hematology (Amsterdam, Netherlands)

Jacobs P, Wood L, Jogessar V.
PMID: 27413882
Hematology. 1998;3(4):299-302. doi: 10.1080/10245332.1998.11746402.

Angiofollicular lymph node hyperplasia is an uncommon low-grade lymphoproliferative disorder first described by Castleman. It is typically asymptomatic with diagnosis incidentally made in young males on chest radiology. Biopsy, in 90% of cases, shows the hyaline vascular variant. In...

Cite
Jacobs P, Wood L, Jogessar V. Refractory Castleman's Disease. Hematology. 1998;3(4):299-302doi: 10.1080/10245332.1998.11746402.
Jacobs, P., Wood, L., & Jogessar, V. (1998). Refractory Castleman's Disease. Hematology (Amsterdam, Netherlands), 3(4), 299-302. https://doi.org/10.1080/10245332.1998.11746402
Jacobs, P, et al. "Refractory Castleman's Disease." Hematology (Amsterdam, Netherlands) vol. 3,4 (1998): 299-302. doi: https://doi.org/10.1080/10245332.1998.11746402
Jacobs P, Wood L, Jogessar V. Refractory Castleman's Disease. Hematology. 1998;3(4):299-302. doi: 10.1080/10245332.1998.11746402. PMID: 27413882.
Copy Download .nbib Format: NLM
Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma.

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)

Francis JH, Abramson DH.
PMID: 26107765
Asia Pac J Ophthalmol (Phila). 2014 Jul-Aug;3(4):241-56. doi: 10.1097/APO.0000000000000079.

PURPOSE: The aim of this study was to discuss the clinical and translational content of the literature as well as advancement in our knowledge pertaining to retinoblastoma and uveal melanoma that were published from January to December 2013.DESIGN: This...

Cite
Francis JH, Abramson DH. Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma. Asia Pac J Ophthalmol (Phila). 2014;3(4):241-56doi: 10.1097/APO.0000000000000079.
Francis, J. H., & Abramson, D. H. (2014). Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 3(4), 241-56. https://doi.org/10.1097/APO.0000000000000079
Francis, Jasmine H, and Abramson, David H. "Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma." Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) vol. 3,4 (2014): 241-56. doi: https://doi.org/10.1097/APO.0000000000000079
Francis JH, Abramson DH. Update on Ophthalmic Oncology 2013: Retinoblastoma and Uveal Melanoma. Asia Pac J Ophthalmol (Phila). 2014 Jul-Aug;3(4):241-56. doi: 10.1097/APO.0000000000000079. PMID: 26107765.
Copy Download .nbib Format: NLM
Current treatment strategies for multiple myeloma.

European journal of internal medicine

Grosbois B, Decaux O, Azais I, Facon T, Avet-Loiseau H.
PMID: 11893464
Eur J Intern Med. 2002 Mar;13(2):85-95. doi: 10.1016/s0953-6205(01)00205-9.

Until 1990, the melphalan-prednisone regimen was the standard treatment for multiple myeloma (MM). The role of alpha-interferon still remains controversial, both in induction therapy and in maintenance therapy. Over the last 10 years, there has been considerable improvement in...

Cite
Grosbois B, Decaux O, Azais I, et al. Current treatment strategies for multiple myeloma. Eur J Intern Med. 2002;13(2):85-95doi: 10.1016/s0953-6205(01)00205-9.
Grosbois, B., Decaux, O., Azais, I., Facon, T., & Avet-Loiseau, H. (2002). Current treatment strategies for multiple myeloma. European journal of internal medicine, 13(2), 85-95. https://doi.org/10.1016/s0953-6205(01)00205-9
Grosbois, Bernard, et al. "Current treatment strategies for multiple myeloma." European journal of internal medicine vol. 13,2 (2002): 85-95. doi: https://doi.org/10.1016/s0953-6205(01)00205-9
Grosbois B, Decaux O, Azais I, Facon T, Avet-Loiseau H. Current treatment strategies for multiple myeloma. Eur J Intern Med. 2002 Mar;13(2):85-95. doi: 10.1016/s0953-6205(01)00205-9. PMID: 11893464.
Copy Download .nbib Format: NLM
Management of Myeloma: Current and Future Approaches.

Cancer control : journal of the Moffitt Cancer Center

Oken MM.
PMID: 10761055
Cancer Control. 1998 May;5(3):218-225. doi: 10.1177/107327489800500302.

BACKGROUND: The treatment of multiple myeloma, relatively stagnant for many years, appears to be entering a promising era for improvement. This paper reviews treatment interventions available for patients with multiple myeloma to indicate a standard approach and to evaluate...

Cite
Oken MM. Management of Myeloma: Current and Future Approaches. Cancer Control. 1998;5(3):218-225doi: 10.1177/107327489800500302.
Oken, M. M. (1998). Management of Myeloma: Current and Future Approaches. Cancer control : journal of the Moffitt Cancer Center, 5(3), 218-225. https://doi.org/10.1177/107327489800500302
Oken. "Management of Myeloma: Current and Future Approaches." Cancer control : journal of the Moffitt Cancer Center vol. 5,3 (1998): 218-225. doi: https://doi.org/10.1177/107327489800500302
Oken MM. Management of Myeloma: Current and Future Approaches. Cancer Control. 1998 May;5(3):218-225. doi: 10.1177/107327489800500302. PMID: 10761055.
Copy Download .nbib Format: NLM
Current treatment in cardiac amyloidosis.

Current treatment options in cardiovascular medicine

Kholová I, Kautzner J.
PMID: 17078911
Curr Treat Options Cardiovasc Med. 2006 Dec;8(6):468-73. doi: 10.1007/s11936-006-0035-5.

Involvement of the heart is a common finding in amyloidosis. The heart is usually infiltrated by amyloid fibrils in primary amyloidosis and age-related forms of amyloidosis, less commonly in transthyretin familial amyloidosis, and rarely in secondary amyloidosis. The most...

Cite
Kholová I, Kautzner J. Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2006;8(6):468-73doi: 10.1007/s11936-006-0035-5.
Kholová, I., & Kautzner, J. (2006). Current treatment in cardiac amyloidosis. Current treatment options in cardiovascular medicine, 8(6), 468-73. https://doi.org/10.1007/s11936-006-0035-5
Kholová, Ivana, and Kautzner, Josef. "Current treatment in cardiac amyloidosis." Current treatment options in cardiovascular medicine vol. 8,6 (2006): 468-73. doi: https://doi.org/10.1007/s11936-006-0035-5
Kholová I, Kautzner J. Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med. 2006 Dec;8(6):468-73. doi: 10.1007/s11936-006-0035-5. PMID: 17078911.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report.

Cases journal

Tahan I, Seale J, Edwards D.
PMID: 18831763
Cases J. 2008 Oct 02;1(1):207. doi: 10.1186/1757-1626-1-207.

BACKGROUND: IgM multiple myeloma is rare disorder, which has clinical, laboratory and radiological manifestations that are consistent with both multiple myeloma and Waldenstrom's macroglobulinaemia.CASE PRESENTATION: An 83 years Welsh lady presented with clinical and radiological features consistent with spinal...

Cite
Tahan I, Seale J, Edwards D. IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report. Cases J. 2008;1(1):207doi: 10.1186/1757-1626-1-207.
Tahan, I., Seale, J., & Edwards, D. (2008). IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report. Cases journal, 1(1), 207. https://doi.org/10.1186/1757-1626-1-207
Tahan, Ihssan, et al. "IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report." Cases journal vol. 1,1 (2008): 207. doi: https://doi.org/10.1186/1757-1626-1-207
Tahan I, Seale J, Edwards D. IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report. Cases J. 2008 Oct 02;1(1):207. doi: 10.1186/1757-1626-1-207. PMID: 18831763; PMCID: PMC2566563.
Copy Download .nbib Format: NLM
Evolving role of high dose stem cell therapy in multiple myeloma.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Gupta A, Kumar L.
PMID: 21731211
Indian J Med Paediatr Oncol. 2011 Jan;32(1):17-24. doi: 10.4103/0971-5851.81885.

Conventional chemotherapy has been used in the treatment of multiple myeloma. However the development of autologous stem cell transplant represented a major advance in its therapy. Complete response (CR) rates to the tune of 40-45% were seen and this...

Cite
Gupta A, Kumar L. Evolving role of high dose stem cell therapy in multiple myeloma. Indian J Med Paediatr Oncol. 2011;32(1):17-24doi: 10.4103/0971-5851.81885.
Gupta, A., & Kumar, L. (2011). Evolving role of high dose stem cell therapy in multiple myeloma. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 32(1), 17-24. https://doi.org/10.4103/0971-5851.81885
Gupta, Ajay, and Kumar, Lalit. "Evolving role of high dose stem cell therapy in multiple myeloma." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 32,1 (2011): 17-24. doi: https://doi.org/10.4103/0971-5851.81885
Gupta A, Kumar L. Evolving role of high dose stem cell therapy in multiple myeloma. Indian J Med Paediatr Oncol. 2011 Jan;32(1):17-24. doi: 10.4103/0971-5851.81885. PMID: 21731211; PMCID: PMC3124984.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 512 entries